Pharmaceuticals
3W leads $43m Series E for China's CANbridge
Hong Kong’s 3W Fund Management has led a $43 million Series E round for CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses cancer and rare diseases.
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
Chinese vision therapy start-up Elumninex raises $50m
Chinese eye disease specialist Elumninex Biosciences has raised a $50 million Series A round led by GL Ventures, Lilly Asia Ventures (LAV), and Quan Capital.
PE-backed Antengene trades flat after $359m HK IPO
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
Sequoia, Matrix back $200m Series A for China’s D3 Bio
D3 Bio, a Chinese drug developer that studies and specifically targets areas where existing approaches to care are not delivering satisfactory outcomes, has raised $200 million in Series A funding.
KKR buys majority stake in New Zealand animal health business
KKR has acquired Argenta, a New Zealand-based animal health services provider, for an undisclosed sum.
Goldman invests $150m in India biosimilars business
Goldman Sachs has invested INR11.2 billion ($150 million) in Biocon Biologics, the biosimilars business of Indian pharmaceuticals manufacturer Biocon, at a post-money valuation of $3.94 billion.
Cell analysis player Cytek raises $120m Series D
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.
China's JW Therapeutics trades up after $300m Hong Kong IPO
JW Therapeutics, a private equity-backed Chinese drug developer specializing in CAR T-cell therapies that engineer immune cells to fight cancers, has raised HK$2.33 billion ($300 million) through a Hong Kong IPO.
China's CARsgen raises $186m Series C
Chinese biotech player CARsgen Therapeutics has raised $186 million in Series C funding led by Loyal Valley Capital.
China biotech player Genecast raises $149m Series E
Genecast Biotechnology, a Chinese gene sequencing and precision diagnostics company, has closed a RMB1 billion ($149 million) Series E funding round led by China Structural Reform Fund.
China's LianBio receives $310m round
LianBio, a Chinese biotech start-up incubated earlier this year by life sciences investor Perceptive Advisors, has raised $310 million from a group featuring BlackRock.
China O2O medicine platform raises $150m
Chinese online-to-offline (O2O) medicine retailer Dingdang Kuaiyao has raised RMB1 billion ($150 million) in an extended Series B round featuring Dragon Gate Investment Partners.
Swedish GP buys Singapore biotech supplier, SBI exits
Swedish private equity firm Summa Equity has acquired a controlling stake in Singapore-based biotech developer Sengenics for an undisclosed sum, setting up an exit for Japan’s SBI Holdings.
3H Health leads $67m Series B for China's EdiGene
China’s 3H Health Investment has led a RMB450 million ($67 million) Series B round for local genetics-based drug discovery and therapeutics developer EdiGene.
PAG-led consortium buys India drug maker
PAG Asia Capital has made its second substantial investment in India in the past two months, leading a consortium that has agreed to acquire a controlling stake in Anjan Drug, a Chennai-based manufacturer of active pharmaceutical ingredients (API).
Lee's Pharmaceutical spin-out gets $145m Series B
Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO), a subsidiary of Lee’s Pharmaceutical, has raised a $145 million Series B round led by Hillhouse Capital and TPG Asia.
Everest Medicines soars on debut after $451m IPO
Everest Medicines, a Chinese biotech start-up backed by CBC Group, performed strongly in early trading in Hong Kong following a HK$3.5 billion ($451 million) IPO.
Genor Biopharma raises $372m in Hong Kong IPO
China-based Genor Biopharma, which counts Hillhouse Capital, Temasek Holdings and Qiming Venture Partners among its investors, has raised HK$2.88 billion ($372 million) through a Hong Kong IPO.
China's Hinova Pharma raises $147m Series C
Hinova Pharma, a Chinese drug developer has raised RMB1 billion ($147 million) in Series C funding from Shenzhen Investment, Hong Kong-listed Tigermed, Huarong Rongde Asset Management, CCB Internationa, and a fund run by Sinopharm Group and CICC Capital.
China healthcare SaaS player Taimei raises $176m
Taimei Technology, a Chinese cloud-based software provider that serves the healthcare sector has raised RMB1.2 billion ($176 million) in funding led by Tencent Holdings, GL Ventures and Yunfeng Capital.
Vision Fund leads $319m round for China's XtalPi
China and US-based artificial intelligence-enabled drug development platform XtalPi has raised $319 million in Series C funding led by SoftBank Vision Fund, the investment arm of insurer PICC Group, and Morningside Venture Capital.
China's InventisBio secures $147m Series D
GL Ventures, the China venture capital arm of Hillhouse Capital, has led a $147 million Series D round for Shanghai-based biotech developer InventisBio.
CDH, SDIC lead $62m Series C for Virogin Biotech
Virogin Biotech, a drug developer based in China and Canada, has received $62 million in Series C funding led by CDH Invesmtents and a subsidiary of State Development and Investment Corporation (SDIC).